Interleukin-6 induces cellular insulin resistance in hepatocytes

Diabetes

Volumn 51, Issue 12, 2002, Pages 3391-3399

  Senn, Joseph J ^a   Klover, Peter J ^a   Nowak, Irena A ^a   Mooney, Robert A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ARTICLE; GLYCOGEN SYNTHESIS; HUMAN; HUMAN CELL; INSULIN METABOLISM; INSULIN RESISTANCE; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0036894360     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.12.3391     Document Type: Article

References (48)

1. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-1292, 1997
2. Fernandez-Real JM, Ricart W: Insulin resistance and inflammation in an evolutionary perspective: The contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 42:1367-1374, 1999
3. Ventre J, Doebber T, Wu M, MacNaul K, Stevens K, Pasparakis M, Kollias G, Moller DE: Targeted disruption of the tumor necrosis factor-α gene: Metabolic consequences in obese and nonobese mice. Diabetes 46:1526-1531, 1997
4. Shiba T, Higashi N, Nishimura Y: Hyperglycaemia due to insulin resistance caused by interferon-gamma. Diabet Med 15:435-436, 1998
5. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745-E751, 2001
6. Yamakawa T, Tanaka S, Yamakawa Y, Kiuchi Y, Isoda F, Kawamoto S, Okuda K, Sekihara H: Augmented production of tumor necrosis factor-alpha in obese mice. Clin Immunol Immunopathol 75:51-56, 1995
7. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS: Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610-614, 1997
8. Nelson KA, Walsh D, Sheehan FA: The cancer anorexia-cachexia syndrome. J Clin Oncol 12:213-225, 1994
9. Pickup JC, Chusney GD, Thomas SM, Burt D: Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 67:291-300, 2000
10. Pradhan AD, Manson JE, Rifai N, Burin JE, Ridker PM: C-Reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
11. Fernandez-Real JM, Broch M, Vendrell J, Gutierrez C, Casamitjana R, Pugeat M, Richart C, Ricart W: Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49:517-520, 2000
12. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metabol 82:4196-4200, 1997
13. Del Aguila LF, Krishnan RK, Ulbrecht JS, Farrell PA, Correll PH, Lang CH, Zierath JR, Kirwan JP: Muscle damage impairs insulin stimulation of IRS-1, PI 3-kinase, and Akt-kinase in human skeletal muscle. Am J Physiol Endocrinol Metab 279:E206-E212, 2000
14. Pedersen BK, Steensberg A, Schjerling P: Muscle-derived interleukin-6: Possible biological effects. J Physiol 536:2:329-337, 2001
15. Sundgren-Andersson AK, Ostlund P, Bartfai T: IL-6 is essential in TNF-alpha-induced fever. Am J Physiol 275: R2028-R2034, 1998
16. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadia CS, Chrousos GP: Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82:4167-4170, 1997
17. Kanemaki T, Kitade H, Kaibori M, Sakitani K, Hiramatsu Y, Kamiyama Y, Ito S, Okumura T: Interleukin 1β and interleukin 6, but not tumor necrosis factorα, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 27:1296-1303, 1998
18. Stouthard JM, Oude Elferink RP, Sauerwein HP: Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes. Biochem Biophys Res Commun 220:241-245, 1996
19. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
20. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970
21. Klaunig JE, Goldblatt PJ, Hinton DE, Lipsky MM, Chacko J, Trump BF: Mouse liver cell culture. I. Hepatocyte isolation. In Vitro 17:913-925, 1981
22. Paysant J, Blanque R, Vasse M, Soria C, Soria J, Gardner CR: Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes. Cytokine 12:774-779, 1999
23. Wang S, Evers BM: Cytokine-mediated differential induction of hepatic activator protein-1 genes. Surgery 123:191-198, 1998
24. Takano A, Haruta T, I: wata M, Usui I, Uno T, Kawahara J, Ueno E, Sasaoka T, Kobayashi, M: Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes. Diabetes 50:1891-1900, 2001
25. Balbis A, Baquiran G, Bergeron JJ, Posner BI: Compartmentalization and insulin-induced translocations of insulin receptor substrates, phosphatidylinositol 3-kinase, and protein kinase B in rat liver. Endocrinology 141:4041-4049, 2000
26. Tremblay F, Marette A: Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. J Biol Chem 276:38052-38060, 2001
27. Perreault M, Marette A: Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7:1138-1143, 2001
28. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNFα and obesity-induced insulin resistance. Science 271:665-668, 1996
29. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes central role of tumor necrosis factor-α. J Clin Invest 94:1543-1549, 1994
30. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A: Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268:26055-26058, 1993
31. Gokhan S, Hotamisligil D, Murray DL, Choy LN, Spiegelman BM: Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 91:4854-4858, 1994
32. Del Aguila LF, Claffey KP, Kirwan JP: TNF-α impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Endocrinol Metab 39:E849-E855, 1999
33. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF: Phosphorylation of SER307 in IRS-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277:1531-1537, 2002
34. Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A, White MF: Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 107:181-189, 2001
35. Tanti JF, Gremeaux T, van Obberghen E, Le Marchand-Brustel Y: Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem 269:6051-6057, 1994
36. Cheung AT, Ree D, Kolls JK, Fuselier J, Coy DH, Bryer-Ash M: An in vivo model for elucidation of the mechanism of tumor necrosis factor-α (TNF-α-induced insulin resistance: Evidence for differential regulation of insulin signaling by TNF-α. Endocrinology 139:4928-4935, 1998
37. Cheung AT, Wang J, Ree D, Kolls JK, Bryer-Ash M: Tumor necrosis factor-α induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. Diabetes 49:810-819, 2000
38. Yamada Y, Webber EM, Kirillova I, Peschon JJ, Fausto N: Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: Requirement for type 1 but not type 2 receptor. Hepatology 28:959-970, 1998
39. Campbell JS, Prichard L, Schaper F, Schmitz J, Stephenson-Famy A, Rosenfeld ME, Argast GM, Heinrich PC, Fausto N: Expression of suppressors of cytokine signaling during liver regeneration. J Clin Invest 107:1285-1292, 2001
40. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson S, Ohlsson C, Jansson J-O: Interleukin-6 deficient mice develp mature-onset obesity. Nature Med 8:75-79, 2002
41. Starr R, Willison TA, Viney EM, Murray LIL, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ: A family of cytokine-inducible inhibitors of signalling. Nature 387:917-921, 1997
42. Mooney RA, Senn J, Cameron S, Inamdar N, Boivin LM, Shang Y, Furlanetto RW: Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. J Biol Chem 276:25889-25893, 2001
43. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E: SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15985-15991, 2000
44. Kawazoe Y, Naka T, Fujimoto M, Kohzaki H, Morita Y, Narazaki M, Okumura K, Saitoh H, Nakagawa R, Uchiyama Y, Akira S, Kishimoto T: Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate (IRS-1) phosphorylation. J Exp Med 193:263-269, 2001
45. Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Van Obberghen E: SOCS-3 inhibits insulin signaling and is upregulated in response to TNF-α in the adipose tissue of obese mice. J Biol Chem 276:47944-47949, 2001
46. Krebs D, Hilton D: SOCS: Physiological suppressors of cytokine signaling. J Cell Sci 113:2813-2819, 2000
47. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108:437-446, 2001
48. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293:1673-1677, 2001